ClinicalTrials.gg
CompletedNCT04649151TeenCoveUpdated Sep 15, 2025Results posted

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

A Phase 2/3 interventional study of mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 53 sites in 2 countries. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
4,328
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
6th of 36
4,328 · median 499
Started
2020
with 3 others
Phase 2/3
4 of 36
none open now
Registered
4th of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 6th largest by enrollment, is one of 4 that started in 2020, is one of 4 in phase 2/3, and was the 4th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series and a booster dose (BD) to an adolescent population. The study will also evaluate the safety and immunogenicity of an mRNA-1273.222 vaccine against the SARS-CoV- 2 omicron variant as a primary series.

Read the detailed description

This is a Phase 2/3 study, with Part 1A (Blinded Phase), Part 1B (Open-label Observational Phase), Part 1C (Booster Dose [BD] Phase), which consists of Part 1C-1 and Part 1C-2, Part 2 (Open-Label), and Part 3 (Open-label). Participants in Part 1A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part 1B of the study is designed to offer participants whose age group becomes Emergency Use Authorization (EUA) eligible to be unblinded so that participants who received placebo in Part 1A can request 2 doses of open-label mRNA-1273 vaccine. Part 1C-1 of the study will offer participants in Part 1A and Part 1B who are at least 5 months from the last dose, the option to request a homologous BD of mRNA-1273. Part 1C-2 is designed to provide a heterologous BD of mRNA-1273 to eligible participants who completed primary COVID-19 vaccination series with a non-Moderna vaccine under EUA and are at least 3 months from the last dose. Part 2 is an open-label design. Participants will receive 2 doses and may receive a booster dose of mRNA-1273 SARS-CoV-2 vaccine. Part 3 is an open-label design. Participants will receive up to 2 doses of mRNA-1273.222 vaccine.

Please access http://TeenCoveStudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • mRNA-1273.222 vaccine
  • SARS-CoV-2 VOC
  • SARS-CoV-2 VOC vaccine
  • Omicron
  • Variant
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 4,328 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Part 1A, Part 2 and Part 3:

  • Participants 12 to \<18 years of age at the time of consent (Screening Visit, Day 0) who, in the opinion of the Investigator, are in good general health based on review of medical history and screening physical examination.
  • Investigator assessment that the participant, in the case of an emancipated minor, or parent(s)/legally acceptable representative(s) (LAR[s]) understand and is willing and physically able to comply with protocol-mandated follow up, including all procedures and provides written /assent.
  • (BMI) at or above the third percentile according to World Health Organization (WHO) Child Growth Standards at the Screening Visit (Day 0)
  • Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche or surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy).
  • Female participants of may be enrolled in the study if the participant has a negative pregnancy test at Screening (Day 0), on the day of the first injection (Day 1), on the day of the second injection (Day 29 in Parts 1A and Part 2, and Day 181 in Part 3); has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1); and has agreed to continue adequate contraception or abstinence through 3 months following the second injection (Day 29 in Part 1A and Part 2, and Day 181 in Part 3).

For Part 1B:

  • Participants must have been previously enrolled in mRNA-1273-P203 study.
  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (Open-Label-Day 1) and on the day of the second injection (Open-Label-Day 29).

For Part 1C-1 Homologous Booster Dose:

  • Participants must have been previously enrolled in the mRNA-1273-P203 study, are actively participating in Part 1A or Part 1B and are least 5 months from the last dose.
  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (BD-Day 1).

Part 1C-2 Heterologous Booster Dose:

  • Male or female, 12 to \< 18 years of age at the time of consent who, in the opinion of the investigator, is in good general health based on review of medical history and screening physical examination AND has completed non-Moderna primary COVID-19 vaccination series under EUA (for example, Pfizer) at least 3 months from consent.

Exclusion criteria

Exclusion Criteria:

For Part 1A, Part 2, and Part 3:

  • Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of product (IP) or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection of COVID-19 within 2 weeks prior to administration of IP (Part 2 participants only). For Part 3 participants, known history of SARS-CoV-2 infection within 90 days prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 90 days prior to administration of IP.
  • Travel outside of the United States or home country (Part 2 and Part 3 only) in the 28 days prior to the Screening Visit (Day 0).
  • Pregnant or breastfeeding
  • Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥38.0°Celsius (C)/≥100.4°Farenheit (F). Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.
  • Prior administration of an investigational coronavirus (for example, SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]) vaccine
  • Current treatment with investigational agents for prophylaxis against COVID-19
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment
  • Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors)
  • History of chronic smoking (≥1 cigarette a day) within 1 year of the Screening Visit (Day 0)
  • History of illegal substance use or alcohol abuse within the past 2 years. This exclusion does not apply to historical cannabis use that was formerly illegal in the participant's state but is legal at the time of screening.
  • History of a diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically:

    • Congenital or acquired immunodeficiency, including (HIV) infection
    • Suspected active hepatitis
    • Has a bleeding disorder that is considered a to IM injection or phlebotomy
    • Dermatologic conditions that could affect local solicited AR assessments
    • History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine
    • Diagnosis of within the previous 10 years (excluding nonmelanoma skin cancer)
    • Febrile seizures
  • Receipt of:

    • Any licensed vaccine within 28 days before the first dose of IP or plans for receipt of any licensed vaccine within 28 days before and/or after each dose of IP.
    • Systemic or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for , ≥20 mg/day prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to the day of enrollment. Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids are allowed.
    • Intravenous blood products (red cells, , immunoglobulins) within 3 months prior to enrollment
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study
  • Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study
  • Is an immediate family member or has a household contact who is an employee of the research center or otherwise involved with the conduct of the study

For Part 1C-1 and Part 1C-2:

  • Pregnant or breastfeeding.
  • Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥ 38.0°C/≥ 100.4°F. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • History of a diagnosis or condition (after enrolment in Part 1A) that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety:

    • Suspected active hepatitis
    • Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy
    • Dermatologic conditions that could affect local solicited AR assessments
    • History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine
    • Diagnosis of malignancy (excluding nonmelanoma skin cancer)
  • Receipt of:

    • Any authorized or licensed vaccine within 28 days before the first dose of IP or plans for receipt of any licensed vaccine through 28 days following the last dose of IP or any seasonal influenza vaccine within 14 days before the first dose of IP or plans for receipt of any seasonal influenza vaccine 14 days following the last dose of IP.
  • Participated in an interventional clinical study, other than mRNA-1273-P203 study, within 28 days prior to the Screening Visit (Day 0 [for Part 1C-1], BD-Day 0 [for Part 1C-2]) or plans to do so while participating in this study.

Part 1C-2 Heterologous Booster Dose:

  • Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID 19 within 2 weeks prior to administration of IP.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,328 participants (actual)

Study arms

  • Experimental
    mRNA-1273

    Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram \[ug\] each), 28 days apart, on Day 1 and Day 29. Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29. Part 2 (Open-Label): Participants will receive 2 IM injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29 and may receive a booster dose on Day 149.

    Biological: mRNA-1273

  • Placebo comparator
    Placebo

    Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.

    Biological: Placebo

  • Experimental
    mRNA-1273 BD

    Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B. Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose.

    Biological: mRNA-1273

  • Experimental
    mRNA-1273.222

    Part 3 (Open-Label): Participants will receive up to 2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart, on Day 1 and Day 181.

    Biological: mRNA-1273.222

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

  • BiologicalmRNA-1273.222

    Sterile solution for injection

07

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Solicited ARs considered causally related to injection were graded 1-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicated lower severity, and higher score indicated greater severity. Investigator reviewed if the solicited AR was recorded as an adverse event (AE) as detailed in the AE section. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the AE section.

    Time frame: 7 days post-vaccination

  2. Number of Participants With Unsolicited AEs

    An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (onset after Day 7 of dosing). An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result or other safety assessment, including one that worsened from baseline and was considered clinically significant by the Investigator was recorded as an AE. Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were classified as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part1/2 but were considered clinical events for efficacy in Part 3 and not AEs. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the AE section.

    Time frame: Up to 28 days post-vaccination

  3. Part 1A Geometric Mean Value of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers From Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Pseudovirus nAb ID50 titers were measured using pseudovirus neutralization assay (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available (LLOQ: 18.5 arbitrary units (AU)/milliliter (mL), ULOQ: 45118 AU/mL). Antibody levels were analyzed using an analysis of covariance (ANCOVA) model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.

    Time frame: Day 57 Study P203/Day 57 Study P301

  4. Part 1A Seroresponse Rate (SRR) for Serum Pseudovirus nAb ID50 in Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Percentage of participants with seroresponse for pseudovirus nAb ID50 measured using PsVNA assay are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ (LLOQ: 18.5 AU/mL), ULOQ: 45118 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.

    Time frame: Day 57 Study P203/Day 57 Study P301

  5. Part 1C-1 Geometric Mean Concentration (GMC) of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Pseudovirus nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10, ULOQ: 281600). PPIS P301: randomly selected participants from study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.

    Time frame: BD Day 29 Study P203/Day 57 Study P301

  6. Part 1C-1 SRR of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above LLOQ (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.

    Time frame: BD Day 29 Study P203/Day 57 Study P301

  7. Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.

    Time frame: Day 29 Study P203/Day 57 Study P301

  8. Part 1C-2 GMC of Post-booster Pseudovirus nAb Against Ancestral Strain at BD Day 29

    Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).

    Time frame: BD Day 29

  9. Part 2 GMC of the Pseudovirus nAb Against Ancestral Strain at Day 57

    Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).

    Time frame: Day 57

  10. Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against SARS-CoV-2 Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.

    Time frame: Day 29 Study P203/Day 57 Study P301

  11. Part 2 SRR of Pseudovirus nAb Against Ancestral Strain

    Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above the LLOQ (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).

    Time frame: Day 57

  12. Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study Discontinuation

    SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. MAAE was an AE that led to an unscheduled visit to a healthcare practitioner, included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and visits to healthcare practitioners external to the study site \[for example, urgent care, primary care physician\]). Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were defined as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part 1/2 but were considered clinical events for efficacy in Part 3 and not AEs.

    Time frame: Day 1 up to Day 751

Secondary outcomes

  1. Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)

    SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 status at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive postbaseline; or positive postbaseline.

    Time frame: Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection

  2. Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection

    Asymptomatic SARS-CoV-2 infection was defined as absence of symptoms and a positive RT-PCR or serology test (bAb levels against SARS-CoV-2 nucleocapsid protein) post dosing in participants who did not have an infection at baseline or pre-Dose 1.

    Time frame: Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection

  3. Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19

    COVID-19 was defined as symptomatic disease based on the following criteria: participants experienced at least 2 of the following systemic symptoms: fever (≥ 38ºC/≥ 100.4ºF), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and had at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2.

    Time frame: Day 43 (14 days after second injection) up to 2.5 months after second injection

  4. Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)

    Secondary case definition of COVID-19 was defined by the following criteria: 1 systemic or respiratory symptoms: fever (temperature \> 38ºC/≥ 100.4ºF), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea, and at least one positive test for SARS-CoV-2.

    Time frame: Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection

  5. Part 1C-1 SRR of the Post-booster Serum Binding Antibody (bAb) Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD

    Percentage of participants with seroresponse for bAb measured using (MesoScale Discovery) MSD are reported. Seroresponse from baseline (pre-Dose 1) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline (pre-Dose 1) is equal to or above the LLOQ.

    Time frame: BD Day 29

  6. Part 1C-1 GMC of Post-booster Pseudovirus nAb Against Variant Strain (B.1.1.529)

    Post-booster Pseudovirus nAb against B.1.1.529 (LLOQ: 8 AU/mL, ULOQ: 24503 AU/mL). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available.

    Time frame: BD Day 29

  7. Part 3 SRR of Serum Pseudovirus nAb Post Dose 1 of mRNA-1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.

    Time frame: Day 29 Study P203/Day 57 Study P301

  8. Part 3 Pseudovirus nAb SRR of Post Dose 1 of mRNA-1273.222 Against Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

    Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.

    Time frame: Day 29 P203/Day 57 P301

  9. Part 3 GM Value of Post Dose 1 (Day 29) of mRNA-1273.222 bAb Against Other Variants of Interest

    mRNA-1273.222 bAb was measured using a S-binding IgG immunoassay. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 397 AU/ml, ULOQ: 2200000 AU/mL).

    Time frame: Day 29

  10. Part 1C-2 GM Value of mRNA-1273 Booster Against Variants of Interest at Day 29

    Time frame: Day 29

  11. Part 1A GM Level of SARS-CoV-2 Spike Protein-specific bAb at Days 1, 57, 209, 394

    SARS-CoV-2 Spike Protein-specific bAb were measured using MSD electrochemiluminescence multiplex assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 69 AU/mL, ULOQ: 14400000 AU/mL).

    Time frame: Days 1, 57, 209, 394

  12. Part 1A GM Value of SARS-CoV-2-Specific nAb at Days 1, 57, 209, 394

    SARS-CoV-2-Specific nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL).

    Time frame: Days 1, 57, 209, 394

  13. Part 1C-1 GM Value of Post-booster Dose Serum bAb Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. B.1.1.7 (LLOQ: 52, ULOQ: 8800000), B.1.351 (LLOQ: 111, ULOQ: 5000000), B.1.617.2 (LLOQ: 49, ULOQ: 7400000), P.1 (LLOQ: 143, ULOQ: 5800000).

    Time frame: BD Day 29

Other outcomes

  1. Number of Deaths Related to Study Drug

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Day 1 up to Day 751

08

Results

Posted Sep 15, 2025
Limitations and caveats
Part 1C-2 enrollment discontinued before planned number of participants. Part 2 discontinued early due to availability of updated variant vaccine (mRNA-1273.222); no hypothesis testing done for primary endpoint/other endpoints not assessed.

Participant flow

The study included Part 1A as the Blinded Phase with participants remaining blinded until the initiation of Part 1B (open-label cross-over vaccination phase), and Parts 1C-1, 1C-2, 2, and 3 as open-label.

Participant flow — Overall Study
MilestonePart 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-2: mRNA-1273 50 μg Booster Dose (BD)Part 2: mRNA-1273 50 μgPart 3: mRNA-1273.222 50 µg
Started2490124315552388
Part 1: 1st injection24861240000
Part 1: 2nd injection24801222000
Part 2: 1st injection000520
Part 2: 2nd injection000500
Part 3: 1 dose0000388
Part 3: 2 doses0000335
Safety analysis set2486124015552388
Solicited safety set2485124012552387
Ppis340013646373
Per protocol (pp) set for efficacy21421044000
Part 2 bd000190
Ppis sars-cov-2 positive (ppis-pos)00044372
Part 1c-1 bd135751000
Part 1b crossover vaccination096000
Part 1c-1 ppis-negative (neg)2670000
Completed12747414341358
Not completed12161169121130
Withdrew: Pregnancy00003
Withdrew: Physician decision100011
Withdrew: Protocol deviation253000
Withdrew: Received another covid-19 vaccine under eua495730000
Withdrew: Withdrawal by subject3701132715
Withdrew: Adverse event10000
Withdrew: Lost to follow-up256291036
Withdrew: Other than specified59294004
Withdrew: Death00001

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Solicited ARs considered causally related to injection were graded 1-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicated lower severity, and higher score indicated greater severity. Investigator reviewed if the solicited AR was recorded as an adverse event (AE) as detailed in the AE section. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the AE section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-1: mRNA-1273 50 µg BDPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μg First InjectionPart 2: mRNA-1273 50 μg Second InjectionPart 2: mRNA-1273 50 μg BDPart 3: mRNA-1273.222 50 μg 1 Dose
Grade 15865856274225187145
Grade 2125029350148169062
Grade 362759150913125
Grade 431000001
Any Solicited (Grade 1-4)246693812789942308233
PrimaryNumber of Participants With Unsolicited AEs

An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (onset after Day 7 of dosing). An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result or other safety assessment, including one that worsened from baseline and was considered clinically significant by the Investigator was recorded as an AE. Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were classified as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part1/2 but were considered clinical events for efficacy in Part 3 and not AEs. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the AE section.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-1: mRNA-1273 50 µg BDPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 2: mRNA-1273 50 μg BDPart 3: mRNA-1273.222 50 μg 1 Dose
Number of Participants With Unsolicited AEs5822372091910252
PrimaryPart 1A Geometric Mean Value of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers From Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Pseudovirus nAb ID50 titers were measured using pseudovirus neutralization assay (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available (LLOQ: 18.5 arbitrary units (AU)/milliliter (mL), ULOQ: 45118 AU/mL). Antibody levels were analyzed using an analysis of covariance (ANCOVA) model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.

Time frame:
Day 57 Study P203/Day 57 Study P301
Reported as:
Geometric mean · titer
Part 1A Geometric Mean Value of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers From Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
titerPart 1A: mRNA-1273 100 μgStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 1A Geometric Mean Value of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers From Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P3011401.670 (1276.218 to 1539.453)1299.855 (1175.380 to 1437.511)
Statistical analysis
  • Part 1A: mRNA-1273 100 μg vs Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg · Gmr: 1.078 · 95% CI 0.940 to 1.237GMR of P203 vs P301
PrimaryPart 1A Seroresponse Rate (SRR) for Serum Pseudovirus nAb ID50 in Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Percentage of participants with seroresponse for pseudovirus nAb ID50 measured using PsVNA assay are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ (LLOQ: 18.5 AU/mL), ULOQ: 45118 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.

Time frame:
Day 57 Study P203/Day 57 Study P301
Reported as:
Number · percentage of participants
Part 1A Seroresponse Rate (SRR) for Serum Pseudovirus nAb ID50 in Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
percentage of participantsPart 1A: mRNA-1273 100 μgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg
Part 1A Seroresponse Rate (SRR) for Serum Pseudovirus nAb ID50 in Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P30198.8 (97.0 to 99.7)99.0 (97.1 to 99.8)
Statistical analysis
  • Part 1A: mRNA-1273 100 μg vs Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg · Percentage difference: -0.2 · 95% CI -2.1 to 1.9SRR difference of P203 vs P301
PrimaryPart 1C-1 Geometric Mean Concentration (GMC) of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Pseudovirus nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10, ULOQ: 281600). PPIS P301: randomly selected participants from study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.

Time frame:
BD Day 29 Study P203/Day 57 Study P301
Reported as:
Geometric mean · arbitrary units (AU)/mL
Part 1C-1 Geometric Mean Concentration (GMC) of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
arbitrary units (AU)/mLPart 1C-1: mRNA-1273 50 µg BDStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 1C-1 Geometric Mean Concentration (GMC) of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P3017102.0 (6553.2 to 7696.8)1400.4 (1272.7 to 1541.0)
Statistical analysis
  • Part 1C-1: mRNA-1273 50 µg BD vs Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg · Gmr: 5.071 · 95% CI 4.477 to 5.745GMR of GMC at BD-Day 29 P203 vs GMC at Day 57 P301
PrimaryPart 1C-1 SRR of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above LLOQ (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.

Time frame:
BD Day 29 Study P203/Day 57 Study P301
Reported as:
Number · percentage of participants
Part 1C-1 SRR of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
percentage of participantsPart 1C-1: mRNA-1273 50 µg BDStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 1C-1 SRR of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301100.0 (98.6 to 100.0)99.3 (97.6 to 99.9)
Statistical analysis
  • Part 1C-1: mRNA-1273 50 µg BD vs Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg · Srr difference: 0.7 · 95% CI -0.8 to 2.4SRR difference of P203 BD-Day 29 vs P301 Day 57
PrimaryPart 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.

Time frame:
Day 29 Study P203/Day 57 Study P301
Reported as:
Geometric mean · AU/mL
Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
AU/mLPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P3012727.8 (2558.7 to 2908.1)56.6 (52.7 to 60.8)
Statistical analysis
  • Part 3: mRNA-1273.222 50 µg vs Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg · Gmr: 48.191 · 95% CI 43.765 to 53.065GMR of P203 vs P301
PrimaryPart 1C-2 GMC of Post-booster Pseudovirus nAb Against Ancestral Strain at BD Day 29

Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).

Time frame:
BD Day 29
Reported as:
Geometric mean · AU/mL
Part 1C-2 GMC of Post-booster Pseudovirus nAb Against Ancestral Strain at BD Day 29
AU/mLPart 1C-2: mRNA-1273 50 μg BD
Part 1C-2 GMC of Post-booster Pseudovirus nAb Against Ancestral Strain at BD Day 299433.4 ± 8496.8
PrimaryPart 2 GMC of the Pseudovirus nAb Against Ancestral Strain at Day 57

Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).

Time frame:
Day 57
Reported as:
Geometric mean · AU/mL
Part 2 GMC of the Pseudovirus nAb Against Ancestral Strain at Day 57
AU/mLPart 2: mRNA-1273 50 μg
Part 2 GMC of the Pseudovirus nAb Against Ancestral Strain at Day 577351.5 ± 5621.7
PrimaryPart 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against SARS-CoV-2 Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.

Time frame:
Day 29 Study P203/Day 57 Study P301
Reported as:
Geometric mean · AU/mL
Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against SARS-CoV-2 Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
AU/mLPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against SARS-CoV-2 Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P3017603.9 (7004.6 to 8254.6)1692.3 (1543.4 to 1855.5)
Statistical analysis
  • Part 3: mRNA-1273.222 50 µg vs Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg · Gmr: 4.493 · 95% CI 3.972 to 5.083GMR of GMC at BD-Day 29 P203 vs GMC at Day 57 P301
PrimaryPart 2 SRR of Pseudovirus nAb Against Ancestral Strain

Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above the LLOQ (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).

Time frame:
Day 57
Reported as:
Number · percentage of participants
Part 2 SRR of Pseudovirus nAb Against Ancestral Strain
percentage of participantsPart 2: mRNA-1273 50 μg
Part 2 SRR of Pseudovirus nAb Against Ancestral Strain91.3 ± 79.2
PrimaryNumber of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study Discontinuation

SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. MAAE was an AE that led to an unscheduled visit to a healthcare practitioner, included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and visits to healthcare practitioners external to the study site \[for example, urgent care, primary care physician\]). Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were defined as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part 1/2 but were considered clinical events for efficacy in Part 3 and not AEs.

Time frame:
Day 1 up to Day 751
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study Discontinuation
ParticipantsPart 1A: mRNA-1273 100 μgPart 1B: mRNA-1273 100 μgPart 1C-1: mRNA-1273 50 µg BDPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 2: mRNA-1273 50 μg BDPart 3: mRNA-1273.222 50 μg
SAEs212930016
AESIs17091003
MAAEs10403154145127183
AEs Leading to Study Discontinuation0000001
SecondaryPart 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)

SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 status at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive postbaseline; or positive postbaseline.

Time frame:
Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
Reported as:
Count of participants · Participants
Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: Placebo
Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)2225
Statistical analysis
  • Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo · VE · Ve: 60.3 · 95% CI 26.6 to 78.6Vaccine efficacy (VE, percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
SecondaryPart 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection

Asymptomatic SARS-CoV-2 infection was defined as absence of symptoms and a positive RT-PCR or serology test (bAb levels against SARS-CoV-2 nucleocapsid protein) post dosing in participants who did not have an infection at baseline or pre-Dose 1.

Time frame:
Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
Reported as:
Count of participants · Participants
Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: Placebo
Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection2016
Statistical analysis
  • Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo · VE · Ve: 43.5 · 95% CI -16.5 to 72.2VE (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
SecondaryPart 1A Number of Participants With a First Occurrence of Symptomatic COVID-19

COVID-19 was defined as symptomatic disease based on the following criteria: participants experienced at least 2 of the following systemic symptoms: fever (≥ 38ºC/≥ 100.4ºF), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and had at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2.

Time frame:
Day 43 (14 days after second injection) up to 2.5 months after second injection
Reported as:
Count of participants · Participants
Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: Placebo
Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-1906
Statistical analysis
  • Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo · VE · Ve: 100.0The 95% CI of the ratio was calculated using the exact method conditional upon the total number of cases, adjusting for person-years.
SecondaryPart 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)

Secondary case definition of COVID-19 was defined by the following criteria: 1 systemic or respiratory symptoms: fever (temperature \> 38ºC/≥ 100.4ºF), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea, and at least one positive test for SARS-CoV-2.

Time frame:
Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
Reported as:
Count of participants · Participants
Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: Placebo
Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)29
Statistical analysis
  • Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo · VE · Ve: 89.9 · 95% CI 51.0 to 98.9VE (percent), was defined as 1 - ratio of incidence rate (mRNA-1273 vs. placebo).
SecondaryPart 1C-1 SRR of the Post-booster Serum Binding Antibody (bAb) Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD

Percentage of participants with seroresponse for bAb measured using (MesoScale Discovery) MSD are reported. Seroresponse from baseline (pre-Dose 1) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline (pre-Dose 1) is equal to or above the LLOQ.

Time frame:
BD Day 29
Reported as:
Number · Percentage of participants
Part 1C-1 SRR of the Post-booster Serum Binding Antibody (bAb) Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD
Percentage of participantsPart 1C-1: mRNA-1273 50 µg BD
B.1.1.7100.0 ± 98.9
B.1.351100.0 ± 98.9
B.1.617.2100.0 ± 98.9
P.1100.0 ± 98.9
SecondaryPart 1C-1 GMC of Post-booster Pseudovirus nAb Against Variant Strain (B.1.1.529)

Post-booster Pseudovirus nAb against B.1.1.529 (LLOQ: 8 AU/mL, ULOQ: 24503 AU/mL). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available.

Time frame:
BD Day 29
Reported as:
Geometric mean · AU/mL
Part 1C-1 GMC of Post-booster Pseudovirus nAb Against Variant Strain (B.1.1.529)
AU/mLPart 1C-1: mRNA-1273 50 µg BD
Part 1C-1 GMC of Post-booster Pseudovirus nAb Against Variant Strain (B.1.1.529)943.4 ± 853.5
SecondaryPart 3 SRR of Serum Pseudovirus nAb Post Dose 1 of mRNA-1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.

Time frame:
Day 29 Study P203/Day 57 Study P301
Reported as:
Number · percentage of participants
Part 3 SRR of Serum Pseudovirus nAb Post Dose 1 of mRNA-1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
percentage of participantsPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 3 SRR of Serum Pseudovirus nAb Post Dose 1 of mRNA-1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P30195.4 (92.8 to 97.3)0.0 (0.0 to 1.2)
SecondaryPart 3 Pseudovirus nAb SRR of Post Dose 1 of mRNA-1273.222 Against Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301

Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.

Time frame:
Day 29 P203/Day 57 P301
Reported as:
Number · percentage of participants
Part 3 Pseudovirus nAb SRR of Post Dose 1 of mRNA-1273.222 Against Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
percentage of participantsPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg
Part 3 Pseudovirus nAb SRR of Post Dose 1 of mRNA-1273.222 Against Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P30194.9 (92.1 to 96.9)99.3 (97.6 to 99.9)
SecondaryPart 3 GM Value of Post Dose 1 (Day 29) of mRNA-1273.222 bAb Against Other Variants of Interest

mRNA-1273.222 bAb was measured using a S-binding IgG immunoassay. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 397 AU/ml, ULOQ: 2200000 AU/mL).

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part 3 GM Value of Post Dose 1 (Day 29) of mRNA-1273.222 bAb Against Other Variants of Interest
AU/mLPart 3: mRNA-1273.222 50 µg
BA.5282734.2 (266581.0 to 299866.1)
AY.4557963.4 (529270.6 to 588211.6)
B.1.1.7434879.0 (412699.2 to 458250.8)
B.1.351431476.5 (409656.1 to 454459.1)
B.1.1.529189826.0 (178578.0 to 201782.5)
P.1471868.9 (446431.3 to 498756.0)
SecondaryPart 1C-2 GM Value of mRNA-1273 Booster Against Variants of Interest at Day 29
Time frame:
Day 29

No measurements were reported for this outcome.

SecondaryPart 1A GM Level of SARS-CoV-2 Spike Protein-specific bAb at Days 1, 57, 209, 394

SARS-CoV-2 Spike Protein-specific bAb were measured using MSD electrochemiluminescence multiplex assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 69 AU/mL, ULOQ: 14400000 AU/mL).

Time frame:
Days 1, 57, 209, 394
Reported as:
Geometric mean · AU/mL
Part 1A GM Level of SARS-CoV-2 Spike Protein-specific bAb at Days 1, 57, 209, 394
AU/mLPart 1A: mRNA-1273 100 μg
Day 165.848 (60.348 to 71.850)
Day 57346830.736 (330758.387 to 363684.079)
Day 20979624.290 (73959.321 to 85723.172)
Day 39458647.246 (52309.921 to 65752.336)
SecondaryPart 1A GM Value of SARS-CoV-2-Specific nAb at Days 1, 57, 209, 394

SARS-CoV-2-Specific nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL).

Time frame:
Days 1, 57, 209, 394
Reported as:
Geometric mean · AU/mL
Part 1A GM Value of SARS-CoV-2-Specific nAb at Days 1, 57, 209, 394
AU/mLPart 1A: mRNA-1273 100 μg
Day 111.249 (10.712 to 11.812)
Day 571868.363 (1758.809 to 1984.742)
Day 209625.363 (583.319 to 670.437)
Day 394550.262 (489.875 to 618.093)
SecondaryPart 1C-1 GM Value of Post-booster Dose Serum bAb Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. B.1.1.7 (LLOQ: 52, ULOQ: 8800000), B.1.351 (LLOQ: 111, ULOQ: 5000000), B.1.617.2 (LLOQ: 49, ULOQ: 7400000), P.1 (LLOQ: 143, ULOQ: 5800000).

Time frame:
BD Day 29
Reported as:
Geometric mean · AU/mL
Part 1C-1 GM Value of Post-booster Dose Serum bAb Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD
AU/mLPart 1C-1: mRNA-1273 50 µg BD
B.1.1.7581097.8 ± 543987.7
B.1.351431569.2 ± 404983.2
B.1.617.2456423.3 ± 429083.9
P.1417277.2 ± 391682.5
Other pre-specifiedNumber of Deaths Related to Study Drug

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Day 1 up to Day 751
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug
ParticipantsPart 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1B: mRNA-1273 100 µgPart 1C-1: mRNA-1273 50 µg BDPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 2: mRNA-1273 50 μg BDPart 3: mRNA-1273.222 50 μg 1 DosePart 3: mRNA-1273.222 50 ug Second Dose
Deaths000000001
Deaths related to study drug000000000

Adverse events

Collected over Day 1 up to Day 751. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A: mRNA-1273 100 μg0/2,486 (0%)21/2,486 (0.8%)943/2,486 (37.9%)
Part 1A: Placebo0/1,240 (0%)4/1,240 (0.3%)155/1,240 (12.5%)
Part 1B: mRNA-1273 100 µg0/96 (0%)2/96 (2.1%)22/96 (22.9%)
Part 1C-1: mRNA-1273 50 µg BD0/1,408 (0%)9/1,408 (0.6%)429/1,408 (30.5%)
Part 1C-2: mRNA-1273 50 μg BD0/155 (0%)3/155 (1.9%)28/155 (18.1%)
Part 2: mRNA-1273 50 μg0/52 (0%)0/52 (0%)12/52 (23.1%)
Part 2: mRNA-1273 50 ug BD0/19 (0%)0/19 (0%)7/19 (36.8%)
Part 3: mRNA1273.222 50 µg 1 Dose0/388 (0%)12/388 (3.1%)77/388 (19.8%)
Part 3: mRNA-1273.222 50 ug Second Dose1/335 (0.3%)4/335 (1.2%)51/335 (15.2%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventPart 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1B: mRNA-1273 100 µgPart 1C-1: mRNA-1273 50 µg BDPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 2: mRNA-1273 50 ug BDPart 3: mRNA1273.222 50 µg 1 DosePart 3: mRNA-1273.222 50 ug Second Dose
Dengue feverInfections and infestations0/24860/12400/960/14080/1550/520/195/3880/335
Road traffic accidentInjury, poisoning and procedural complications0/24860/12401/960/14080/1550/520/190/3880/335
Suicidal ideationPsychiatric disorders5/24860/12401/962/14080/1550/520/190/3880/335
Anaphylactic reactionImmune system disorders0/24860/12400/960/14081/1550/520/190/3880/335
SeizureNervous system disorders0/24860/12400/960/14081/1550/520/190/3880/335
NephrolithiasisRenal and urinary disorders0/24860/12400/960/14081/1550/520/190/3880/335
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/24860/12400/960/14080/1550/520/190/3882/335
Normochromic normocytic anaemiaBlood and lymphatic system disorders0/24860/12400/960/14080/1550/520/190/3881/335
PeritonitisInfections and infestations0/24860/12400/960/14080/1550/520/190/3881/335
Gun shot woundInjury, poisoning and procedural complications0/24860/12400/960/14080/1550/520/190/3881/335
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPart 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1B: mRNA-1273 100 µgPart 1C-1: mRNA-1273 50 µg BDPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 2: mRNA-1273 50 ug BDPart 3: mRNA1273.222 50 µg 1 DosePart 3: mRNA-1273.222 50 ug Second Dose
COVID-19Infections and infestations382/248634/124011/96257/140810/1553/523/190/3880/335
InfluenzaInfections and infestations19/24860/12401/9630/14087/1551/522/195/3880/335
Upper respiratory tract infectionInfections and infestations257/248628/12403/9681/14086/1552/521/194/3880/335
NasopharyngitisInfections and infestations60/24866/12404/9616/14080/1550/520/1930/38823/335
Respiratory tract infectionInfections and infestations11/24864/12400/962/14081/1550/520/1926/38822/335
Asymptomatic COVID-19Infections and infestations81/248625/12406/9639/14082/1552/520/190/3880/335
Attention deficit hyperactivity disorderPsychiatric disorders41/24866/12400/9614/14082/1553/520/190/3880/335
Injection site lymphadenopathyGeneral disorders137/24866/12400/965/14080/1551/520/190/3880/335
Abdominal painGastrointestinal disorders8/24863/12400/966/14080/1550/521/191/3881/335
Parainfluenzae virus infectionInfections and infestations3/24860/12401/962/14081/1550/521/191/3880/335

Baseline characteristics

Part 1A Randomization Set: All participants who were randomized. Parts 1C-2, 2, and 3 Safety Set: participants who received at least 1 dose of study drug in Study mRNA-1273-P203 (P203). Study mRNA-1273-P301 (P301) (NCT04470427) mRNA-1273 100 μg: PPIS of randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria.

Age, Customized
Age, Customized(Participants)Part 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P203 — Adolescents (12-17 years)249012431555238804328
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P203 — Adults (18-64 years)0000000
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Adolescents (12-17 years)0000000
Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Adults (18-64 years)00000296296
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Sex Data for Participants Enrolled in Study mRNA-1273-P203 — Female1206607782618502102
Sex Data for Participants Enrolled in Study mRNA-1273-P203 — Male1284636772620302226
Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Female00000153153
Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Male00000143143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P203 — Hispanic or Latino28015237143670850
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P203 — Not Hispanic or Latino21901079116362103442
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P203 — Unknown or Not Reported2012220036
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Hispanic or Latino000007878
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Not Hispanic or Latino00000216216
Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown or Not Reported0000022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1A: mRNA-1273 100 μgPart 1A: PlaceboPart 1C-2: mRNA-1273 50 μg BDPart 2: mRNA-1273 50 μgPart 3: mRNA-1273.222 50 µgStudy mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μgTotal
Race Data for Participants Enrolled in Study mRNA-1273-P203 — White20871043115303903314
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Black or African American834223181260292
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Asian143803300229
Race Data for Participants Enrolled in Study mRNA-1273-P203 — American Indian or Alaska Native127101021
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Native Hawaiian or Other Pacific Islander3000003
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Multiple118509030180
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Other279402190259
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Not Reported1111000022
Race Data for Participants Enrolled in Study mRNA-1273-P203 — Unknown6101008
Race Data for Participants Enrolled in Study mRNA-1273-P301 — White00000207207
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Black or African American000002929
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Asian000003030
Race Data for Participants Enrolled in Study mRNA-1273-P301 — American Indian or Alaska Native0000033
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Native Hawaiian or Other Pacific Islander0000022
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Multiple000001414
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Other0000088
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Not Reported0000033
Race Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown0000000
09

Study locations

53 sites
  • Velocity Clinical Research - Banning
    Banning, California 92220, United States
  • Paradigm Clinical Research
    La Mesa, California 91942, United States
  • Altus Research - Hunt - PPDS
    Lake Worth, Florida 33461, United States
  • Accel Research Sites - Nona Pediatric Center - ERN - PPDS
    Orlando, Florida 32829, United States
  • Tekton Research - Georgia - PPDS
    Chamblee, Georgia 30341, United States
  • IACT Health - Roswell - IACT - HyperCore - PPDS
    Columbus, Georgia 31904, United States
  • Meridian Clinical Research - (Macon Georgia) - Platinum - PPDS
    Macon, Georgia 31210, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research - Boise - PPDS
    Meridian, Idaho 83642, United States
  • Olivo Medical and Wellness Center
    Chicago, Illinois 60618, United States
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46383, United States
  • Meridian Clinical Research (Sioux City - Iowa)
    Sioux City, Iowa 51106, United States
  • Alliance for Multispecialty Research -El Dorado
    El Dorado, Kansas 67042, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Velocity Clinical Research - Metairie - PPDS
    Metairie, Louisiana 70006, United States
  • University of Massachusetts Medical School, Molecu
    Worcester, Massachusetts 01655, United States
  • Clinical Research Institute, Inc - CRN - PPDS
    Minneapolis, Minnesota 55402, United States
  • Velocity Clinical Research - Gulfport - PPDS
    Gulfport, Mississippi 39503, United States
  • Sundance Clinical Research - Platinum - PPDS
    St Louis, Missouri 63141, United States
  • Meridian Clinical Research (Hastings-Nebraska) - Platinum - PPDS
    Hastings, Nebraska 68901, United States
  • Quality Clinical Research - HyperCore - PPDS
    Omaha, Nebraska 68114, United States
  • Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDS
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research - Albuquerque - PPDS
    Albuquerque, New Mexico 87102, United States
  • Child Healthcare Associates - East Syracuse
    East Syracuse, New York 13210, United States
  • Meridian Clinical Research (Endwell-New York) - Platinum - PPDS
    Endwell, New York 13901, United States
  • Velocity Clinical Research - Cincinnati - PPDS
    Cincinnati, Ohio 45242, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Vital Prospects Clinical Research Institute PC - CRN - PPDS
    Tulsa, Oklahoma 74136, United States
  • Cyn3rgy Research - ClinEdge - PPDS
    Gresham, Oregon 97030, United States
  • Velocity Clinical Research - Providence - PPDS
    East Greenwich, Rhode Island 02818, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414, United States
  • Meridian Clinical Research - Charleston, SC
    Charleston, South Carolina 29414, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Coastal Bend Research Center
    Corpus Christi, Texas 78404, United States
  • ACRC Trials
    Frisco, Texas 75033, United States
  • DM Clinical Research - Kool Kids Pediatrics - ERN - PPDS
    Houston, Texas 77064, United States
  • Clinical Trials of Texas, Inc. - PPDS
    San Antonio, Texas 78229, United States
  • Tekton Research
    San Antonio, Texas 78229, United States
  • Tekton Research
    San Antonio, Texas 78244, United States
  • Cope Family Medicine - Ogden Clinic - CCT
    Bountiful, Utah 84010, United States
  • Wee Care Pediatrics - Kaysville
    Kaysville, Utah 84037, United States
  • Cottonwood Pediatrics
    Murray, Utah 84107, United States
  • South Ogden Family Medicine/Ogden Clinic - CCT Research
    South Ogden, Utah 84405, United States
  • Alliance for Multispecialty Research
    Syracuse, Utah 84075, United States
  • Advanced Clinical Research - Jordan Valley - ERN - PPDS
    West Jordan, Utah 84088, United States
  • Meridian Clinical Research (Norfolk, Virginia)
    Norfolk, Virginia 68701, United States
  • Meridian Clinical Research - Family Practice Ports - Portsmouth - Platinum - PPDS
    Portsmouth, Virginia 23703, United States
  • Caimed Dominicana S.A.S
    Santo Domingo, Nacional, Dominican Republic
  • Hospital General Regional Dr. Marcelino Velez Santana
    Santo Domingo, Nacional, Dominican Republic
  • Hospital Materno Infantil San Lorenzo de Los Mina
    Santo Domingo, Nacional, Dominican Republic
  • Instituto Dermatologico y Cirugia de la Piel Dr. H Sede San Cristóbal
    Santo Domingo, Nacional, Dominican Republic
  • Instituto Dominicano de Estudios Virologicos IDEV
    Santo Domingo, Nacional, Dominican Republic
10

References and documents

Publications

  • Figueroa AL, Torres D, Reyes-Acuna C, Matherne P, Yeakey A, Deng W, Xu W, Sigal Y, Chambers G, Olsen M, Girard B, Miller JM, Das R, Priddy F. Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial. Lancet Infect Dis. 2025 Feb;25(2):208-217. doi: 10.1016/S1473-3099(24)00501-2. Epub 2024 Sep 24. PubMed 39332418 ↗
  • Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, Ding B, Dooley J, Girard B, Hillebrand W, Pajon R, Miller JM, Leav B, McPhee R. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. 2021 Dec 9;385(24):2241-2251. doi: 10.1056/NEJMoa2109522. Epub 2021 Aug 11. PubMed 34379915 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jun 2024, 42 months.

Results were first posted in Sep 2025, 1 year 3 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 42 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 2, 2020
StartActual
Dec 9, 2020
Primary completionActual
Jun 14, 2024
CompletionActual
Jun 14, 2024
Results first posted
Sep 15, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04649151
Lead sponsor
ModernaTX, Inc.
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Dec 9, 2020
Primary completion
Jun 14, 2024
Completion
Jun 14, 2024
Results posted
Sep 15, 2025
Last update
Sep 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · Elasomeran/Davesomeran

Start the discussion